like_老虎社区_美港股上老虎

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":609334319,"tweetId":"609334319","gmtCreate":1638237795531,"gmtModify":1638237795727,"author":{"id":3579785829632833,"idStr":"3579785829632833","authorId":3579785829632833,"authorIdStr":"3579785829632833","name":"Hynne","avatar":"https://static.tigerbbs.com/f2a786289d732ce5829c1b81bf2b5e30","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":36,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>like</p></body></html>","htmlText":"<html><head></head><body><p>like</p></body></html>","text":"like","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/609334319","repostId":1132612794,"repostType":4,"repost":{"id":"1132612794","kind":"news","pubTimestamp":1638237676,"share":"https://www.laohu8.com/m/news/1132612794?lang=&edition=full","pubTime":"2021-11-30 10:01","market":"us","language":"en","title":"IBIO Stock Surges as the Biotech Company Looks to Leverage Omicron Fears","url":"https://stock-news.laohu8.com/highlight/detail?id=1132612794","media":"InvestorPlace","summary":"News of the omicron variant of Covid-19 has sent vaccine makers into a frenzy, as companies race to ","content":"<p>News of the omicron variant of Covid-19 has sent vaccine makers into a frenzy, as companies race to make further adaptations. Many of the leadingvaccine makers have already begun testingand developing new products. But there is also one lesser-known name seizing on an opportunity to better establish itself. This company,<b>iBio</b>(NYSEMKT:<b><u>IBIO</u></b>), trades at less than $1, but IBIO stock has been rising all day on vaccine speculation. In fact, shares closed up 29%.</p>\n<p>What Happened With IBIO Stock</p>\n<p>Investors may recall that iBio is not exactly a&nbsp;<i>new</i>&nbsp;name to the vaccine race. In fact, earlier in the pandemic, IBIO stock popped on its hopes for fighting Covid-19. However, with companies like&nbsp;<b>Moderna</b>(NASDAQ:<b><u>MRNA</u></b>) and&nbsp;<b>Pfizer</b>(NYSE:<b><u>PFE</u></b>) pulling ahead, iBio has been stuck on the sidelines. Many experts have therefore written it off as a formermeme stockwith no further utility.</p>\n<p>Today, the company is changing that narrative.&nbsp;This growth likely stems from the fact that the company has worked hard to leverage fear of the growing variant, emphasizing the need for new vaccines. As Chairman and CEO Tom Isett noted in a statement released by the company:</p>\n<blockquote>\n “The emergence of Omicron has strengthened our belief that a next-generation vaccine development strategy such as iBio’s, which targets the genetically more conserved nucleocapsid, or N, protein rather than the mutable S protein, is needed to help overcome this pandemic.”\n</blockquote>\n<p>Why It Matters</p>\n<p>It’s clear that the company is correct in its sentiment that the sudden rise of the omicron variant has highlighted the need for further vaccine innovation. It’s also clear that the variant’s mutations stand to pose a unique challenge to vaccine developers. While each variant has been different than previously detected strains, none so far has included a mutation count as high as that of omicron. So far, the latest strain isthought to include 30 mutations.</p>\n<p>This could provide a unique opportunity for iBio, though. Isett also shared that the company is expecting feedback from the U.S. Food and Drug Administration in 2022.</p>\n<p>What It Means</p>\n<p>While most of the surges that we saw from vaccine producers across the board today were the product of speculation and media buzz, iBio certainly stands to benefit if it has, in fact, identified a unique area of vaccine development that could help combat the new variant and the threat it poses.</p>\n<p>It’s hard to assess the future of a company, particularly one trading at penny stock levels, when its rise has been the result of speculation. That said, iBio stands out from its competitors today, in no small part because its statement on the recent news involving its industry was different.</p>\n<p>We’re still learning about the omicron variant and the extent to which it will effect current vaccines, but IBIO stock is certainly worth watching as it develops.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IBIO Stock Surges as the Biotech Company Looks to Leverage Omicron Fears</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIBIO Stock Surges as the Biotech Company Looks to Leverage Omicron Fears\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 10:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/11/ibio-stock-surges-as-the-biotech-company-looks-to-leverage-omicron-fears/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>News of the omicron variant of Covid-19 has sent vaccine makers into a frenzy, as companies race to make further adaptations. Many of the leadingvaccine makers have already begun testingand developing...</p>\n\n<a href=\"https://investorplace.com/2021/11/ibio-stock-surges-as-the-biotech-company-looks-to-leverage-omicron-fears/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IBIO":"iBio Inc."},"source_url":"https://investorplace.com/2021/11/ibio-stock-surges-as-the-biotech-company-looks-to-leverage-omicron-fears/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1132612794","content_text":"News of the omicron variant of Covid-19 has sent vaccine makers into a frenzy, as companies race to make further adaptations. Many of the leadingvaccine makers have already begun testingand developing new products. But there is also one lesser-known name seizing on an opportunity to better establish itself. This company,iBio(NYSEMKT:IBIO), trades at less than $1, but IBIO stock has been rising all day on vaccine speculation. In fact, shares closed up 29%.\nWhat Happened With IBIO Stock\nInvestors may recall that iBio is not exactly a new name to the vaccine race. In fact, earlier in the pandemic, IBIO stock popped on its hopes for fighting Covid-19. However, with companies like Moderna(NASDAQ:MRNA) and Pfizer(NYSE:PFE) pulling ahead, iBio has been stuck on the sidelines. Many experts have therefore written it off as a formermeme stockwith no further utility.\nToday, the company is changing that narrative. This growth likely stems from the fact that the company has worked hard to leverage fear of the growing variant, emphasizing the need for new vaccines. As Chairman and CEO Tom Isett noted in a statement released by the company:\n\n “The emergence of Omicron has strengthened our belief that a next-generation vaccine development strategy such as iBio’s, which targets the genetically more conserved nucleocapsid, or N, protein rather than the mutable S protein, is needed to help overcome this pandemic.”\n\nWhy It Matters\nIt’s clear that the company is correct in its sentiment that the sudden rise of the omicron variant has highlighted the need for further vaccine innovation. It’s also clear that the variant’s mutations stand to pose a unique challenge to vaccine developers. While each variant has been different than previously detected strains, none so far has included a mutation count as high as that of omicron. So far, the latest strain isthought to include 30 mutations.\nThis could provide a unique opportunity for iBio, though. Isett also shared that the company is expecting feedback from the U.S. Food and Drug Administration in 2022.\nWhat It Means\nWhile most of the surges that we saw from vaccine producers across the board today were the product of speculation and media buzz, iBio certainly stands to benefit if it has, in fact, identified a unique area of vaccine development that could help combat the new variant and the threat it poses.\nIt’s hard to assess the future of a company, particularly one trading at penny stock levels, when its rise has been the result of speculation. That said, iBio stands out from its competitors today, in no small part because its statement on the recent news involving its industry was different.\nWe’re still learning about the omicron variant and the extent to which it will effect current vaccines, but IBIO stock is certainly worth watching as it develops.","news_type":1},"isVote":1,"tweetType":1,"viewCount":755,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/609334319"}